Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a is a small scale open phase two interventional study to assess long-term
stabilising effects of on neurological symptoms by regular intrathecal administered
monoclonal antibodies in progressive multiple sclerosis.